BVT 28949
Alternative Names: BVT.28949Latest Information Update: 22 Feb 2010
Price :
$50 *
At a glance
- Originator Biovitrum
- Developer Swedish Orphan Biovitrum
- Class Antiglaucomas
- Mechanism of Action Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 22 Feb 2010 No development reported - Phase-II for Glaucoma in Sweden (Ophthalmic)
- 22 Feb 2010 No development reported - Phase-II for Glaucoma in Ukraine (Ophthalmic)
- 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum